Skip to content

MaxCyte MXCT Debt-to-assets

Debt-to-assets at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
0.1×0.0×
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
0.4×0.0×
Ginkgo Bioworks logo
Ginkgo BioworksDNA
0.4×+0.1×
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
0.0×
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
0.4×+0.3×
PDE
Pro-Dex, Inc.PDEX
0.2×0.0×

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Calculated from MaxCyte’s reported figures.

Based on the most recent quarter.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's debt-to-assets?
MaxCyte (MXCT) reported debt-to-assets of 0.1× in Q1 2026.
How has MaxCyte's debt-to-assets changed year-over-year?
MaxCyte's debt-to-assets increased by 9.9% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for MaxCyte's debt-to-assets?
Over 5 years (2020 to 2025), MaxCyte's debt-to-assets has grown at a -8.0% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.